RecruitingBladder Cancer
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Sponsor: AstraZeneca
You may qualify if…
- ✓ Age ≥ 18 years;
- ✓ Signed ICF, including consent for FFPE tumor tissue sample testing;
- ✓ Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
- ✓ For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:
- ✓ T1 tumor
- ✓ High grade/G3 tumor
- ✓ CIS (carcinoma in situ)
- ✓ Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);
You may not qualify if…
- ✕ Participation in any interventional trial since the urothelial bladder cancer diagnosis.
Source: ClinicalTrials.gov · NCT07038928 · last updated 2026-08-10